Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
METRO-P: Metronomic Oral Paclitaxel Monotherapy in Advanced HER2-Negative Breast Cancer
ChiCTR2600130144Phase 4Not yet recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of paclitaxel in breast cancer (5 arms), sponsored by Zhejiang Cancer Hospital. Primary endpoints: Progression-Free Survival, Disease Control Rate and 1 more. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
paclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2600130144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600130144.